SHH · 600267.SS
Zhejiang Hisun Pharmaceutical Co., Ltd.
CN¥12.95+CN¥0.23 (+1.81%)
Zhejiang Hisun Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 13.67% below the high.
Loading market information…
SHH · 688091.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Shanghai Yizhong Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Shanghai Yizhong Pharmaceutical Co., Ltd.’s forward annual dividend is CN¥0.31 per share, paid annual. The forward yield is 0.89% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shanghai Yizhong Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥12.95+CN¥0.23 (+1.81%)
Zhejiang Hisun Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 13.67% below the high.
CN¥22.00+CN¥2.00 (+10.0%)
Henan Lingrui Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.98% below the high.
CN¥15.04+CN¥0.54 (+3.72%)
Guobang Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.77% below the high.
CN¥8.16+CN¥0.10 (+1.24%)
Shanghai Shyndec Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.42% below the high.
CN¥17.50+CN¥0.05 (+0.29%)
Xiamen Kingdomway Group Company’s quoted price sits in the upper half of its reported 52-week range, 18.68% below the high.
CN¥24.26+CN¥0.21 (+0.87%)
Mayinglong Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.62% below the high.
CN¥3.07-CN¥0.01 (-0.32%)
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 23.06% below the high.
CN¥19.86-CN¥0.29 (-1.44%)
Shenzhen Chipscreen Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.54% below the high.
